Alexey Alexeevich Kubanov

Alexey Alexeevich Kubanov

Auto-generated profile, based on publicly available information

Alexey Alexeevich Kubanov

State Research Center of Dermatovenereology and Cosmetology

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in The Lancet
Verified
Journal Article
Closed access
HBHervé Bachelez
Hervé Bachelez
PKPeter C M van de Kerkhof
Peter C M van de Kerkhof
RSRobert Strohal
Robert Strohal
AKAlexey Kubanov
Alexey Kubanov
FVFernando Valenzuela
Fernando Valenzuela
RWRobert Wolk
Robert Wolk

1 January 2017 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
AGAlice Gottlieb
Alice Gottlieb
JSJohn Sullivan
John Sullivan
MDMartijn van Doorn
Martijn van Doorn
AKAlexey Kubanov
Alexey Kubanov
RYRuquan You
Ruquan You
MMMarina Milutinovic
Marina Milutinovic
Plaque psoriasis affecting palms and soles is disabling and often resistant to treatment. Evaluate the efficacy and safety of secukinumab, an anti-interleukin 17A antibody, in subjects with palmoplantar psoriasis. In this double-blinded, randomized controlled trial, 205 subjects were randomized 1:1:1 to secukinumab 300 mg, 150 mg, or placebo. The primary endpoint was Palmoplantar Investigator's Global Assessment (ppIGA) 0 (clear) or 1 (almost clear/minimal) response at week 16. At week 16, the percentage of subjects who achieved clear or almost clear palms and soles (or ppIGA 0/1) with secukinumab 300 mg (33.3%) and 150 mg (22.1%) was superior to the percentage achieved with placebo (1.5%, P < .001). Palmoplantar Psoriasis Area and Severity Index (ppPASI) was significantly reduced with secukinumab 300 mg (-54.5%) and 150 mg (-35.3%) compared with placebo (-4.0%, P < .001). Dermatology Life Quality Index (DLQI) 0/1 responses from subjects in the secukinumab groups were also significantly higher compared with placebo at week 16 (P < .01) and pain and function of palms and soles was markedly improved with secukinumab as measured by the palmoplantar Quality-of-Life Instrument. Secukinumab 300 mg consistently showed the best outcomes. The safety profile was favorable and similar to previous studies. Lack of active comparator. In GESTURE, the largest randomized controlled trial in palmoplantar psoriasis, secukinumab demonstrated the greatest efficacy to date for treating difficult-to-treat psoriasis.

24 July 2015 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
AKA. A. Kubanov
A. A. Kubanov
OKO. R. Katunina
O. R. Katunina
VCV. V. Chikin
V. V. Chikin

25 July 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Boris Leonidovich ShaskolskiyBoris Leonidovich Shaskolskiy
Boris Leonidovich Shaskolskiy
EDEkaterina Dementieva
Ekaterina Dementieva
Ilya KandinovIlya Kandinov
Ilya Kandinov
MFMarina Filippova
Marina Filippova
NPNatalia Petrova
Natalia Petrova
Dmitry GryadunovDmitry Gryadunov
Dmitry Gryadunov
The goal of this work was to study the phenotypic susceptibility and resistance determinants of N. gonorrhoeae isolates to beta-lactam antimicrobials (benzylpenicillin and ceftriaxone). A total of 522 clinical isolates collected in Russia in 2015–2017 were analysed for susceptibility using the agar dilution method. DNA loci involved in antimicrobial resistance were identified using DNA microarray analysis and sequencing. Resistance to benzylpenicillin remained high, with 7.7% of isolates resistant (MICpen > 1 mg/L) and 47.5% of isolates showing intermediate susceptibility (MICpen = 0.12–1 mg/L). The most frequent resistance determinant (72.4% isolates) was the Asp345 insertion in penA, both as a single mutation and in combination with other mutations, particularly with the substitution Leu421Pro in ponA (39.0%). Mutations affecting the influx and efflux of drugs were also found, including amino acid substitutions in PorB (26.8% isolates) and delA in the promoter region of mtrR (22.8%). The accumulation of mutations in chromosomal genes (penA, pon, porA, and mtrR) led to a stepwise increase in MICpen to values characteristic of intermediate resistance. The presence of blaTEM plasmids was found in 25 isolates (4.8%), resulting in a strong increase in resistance to penicillin (MICpen > 16 mg/L) compared with the chromosomal mutations; 23 plasmids were of the African type with TEM-1 beta-lactamase, and two plasmids were of the Toronto/Rio type with TEM-135 beta-lactamase. Only three isolates were found with reduced susceptibility to ceftriaxone, with MICcef = 0.12–0.25 mg/L. Sequencing of penA did not reveal mutations associated with resistance to third-generation cephalosporins, and the gene structure was non-mosaic. The majority of isolates (21 of 25) carrying the blaTEM plasmid also contained the conjugative plasmid with tetM (resistance to tetracyclines), consistent with previously reported data that the presence of the conjugative plasmid facilitates the transfer of other plasmids associated with antimicrobial resistance.

9 August 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AKAlexey Kubanov
Alexey Kubanov
DVDenis Vorobyev
Denis Vorobyev
ACAleksandr Chestkov
Aleksandr Chestkov
ALArvo Leinsoo
Arvo Leinsoo
Boris Leonidovich ShaskolskiyBoris Leonidovich Shaskolskiy
Boris Leonidovich Shaskolskiy
Dmitry DeryabinDmitry Deryabin
Dmitry Deryabin
The widespread distribution of Neisseria gonorrhoeae strains that are resistant to previously used and clinically implemented antibiotics is a significant global public health problem. In line with WHO standards, the national Gonococcal Antimicrobial Surveillance Programme (RU-GASP) has been in existence in Russia since 2004; herein, the current status (2015) is described, including associations between N. gonorrhoeae antimicrobial susceptibility, primary genetic resistance determinants and specific strain sequence types. A total of 124 N. gonorrhoeae strains obtained from 9 regions in Russia in 2015 were examined using N. gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST), an antimicrobial susceptibility test according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria and an oligonucleotide microarray for the identification of mutations in the penA, ponA, rpsJ, gyrA and parC genes responsible for penicillin G, tetracycline, and fluoroquinolone resistance. Genogroup (G) isolates were evaluated based on their porB and tbpB sequence types (STs). NG-MAST analysis showed a diversified population of N. gonorrhoeae in Russia with 58 sequence types, 35 of which were described for the first time. The STs 807, 1544, 1993, 5714, 9476 and 12531, which were typical for some Russian Federation regions and several countries of the former Soviet Union, were represented by five or more isolates. The internationally widespread ST 1407 was represented by a single strain in the present study. Division into genogroups facilitated an exploration of the associations between N. gonorrhoeae sequence type, antimicrobial resistance spectra and genetic resistance determinant contents. Preliminarily susceptible (G-807, G-12531) and resistant (G-5714, G-9476) genogroups were revealed. The variability in the most frequently observed STs and genogroups in each participating region indicated geographically restricted antimicrobial susceptibility in N. gonorrhoeae populations. Resistance or intermediate susceptibility to previously recommended antimicrobials, such as penicillin G (60.5 %), ciprofloxacin (41.1 %) and tetracycline (25 %), is common in the N. gonorrhoeae population. Based on previous reports and current data, ceftriaxone and spectinomycin should be recommended for first-line empiric antimicrobial monotherapy for gonorrhoea in Russia.

8 July 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AGA.B. Gottlieb
A.B. Gottlieb
AKA. Kubanov
A. Kubanov
MDM. Doorn
M. Doorn
JSJ. Sullivan
J. Sullivan
KPK.A. Papp
K.A. Papp
JFJ.A. Frueh
J.A. Frueh